{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,13]],"date-time":"2026-02-13T21:56:41Z","timestamp":1771019801317,"version":"3.50.1"},"reference-count":18,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2023,11,16]],"date-time":"2023-11-16T00:00:00Z","timestamp":1700092800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,12,22]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Phosphodiesterase type 5 (PDE5) inhibitor labeling states that these agents should not be used in conjunction with other erectogenic medications for fear of priapism occurring.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Aim<\/jats:title>\n                  <jats:p>We explored the risk of priapism and prolonged erections in men in our post\u2013radical prostatectomy (RP) penile injection program who were using regular PDE5 inhibitor and intracavernosal injections (ICIs) as part of their rehabilitation program.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>The study cohort included men on penile injection therapy who (1) were taking tadalafil 5\u00a0mg daily or taking sildenafil 25\u00a0mg on noninjection days, (2) had an RP, (3) were using their respective PDE5 inhibitor regularly at the time of penile injection training, and (4) complied with the program instructions regarding penile injection use. Demographics, comorbidity details, PDE5 inhibitor dose and utilization, and injection dose and utilization data were collected. All patients underwent in-office injection training and used trimix (papaverine\/phentolamine\/prostaglandin E1) as the intracavernosal medication.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Outcomes<\/jats:title>\n                  <jats:p>Priapism was defined as a patient self-reported penetration hardness erection \u22654\u00a0hours in duration, while prolonged erection was defined as a penetration hardness erection lasting \u22652\u00a0hours.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>A total of 112 tadalafil users and 364 sildenafil users were compared. Mean age and duration post-RP were 62\u2009\u00b1\u200914\u00a0years and 5.2\u2009\u00b1\u200912\u00a0months, respectively, and there was no difference between tadalafil and sildenafil groups. The mean trimix dose was tadalafil 24\u2009\u00b1\u200924\u00a0units and sildenafil 31\u2009\u00b1\u200937\u00a0units (P\u00a0&amp;lt;\u2009.05). Priapism occurred in 2 (1.7%) of 112 tadalafil users and 5 (1.4%) of 364 sildenafil users (P\u00a0=\u2009.47). Excluding those men experiencing priapism on any occasion, those with any reported penetration hardness erection lasting \u22652\u00a0hours were 7 (6.3%) of 112 tadalafil users and 12 (3.3%) of 364 sildenafil users (P\u00a0&amp;lt;\u2009.01). A total of 53% of these prolonged erections occurred within the first 6 injections at home (no difference between tadalafil and sildenafil groups).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Clinical Implications<\/jats:title>\n                  <jats:p>We emphasize the need for continued monitoring and education on proper injection techniques to minimize the risk of adverse events in ICI and PDE5 inhibitor combination therapy.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Strengths &amp; Limitations<\/jats:title>\n                  <jats:p>This study has a relatively large patient population with a considerable follow-up time. Additionally, the rigorous training, education, and monitoring of the participants, as well as the use of formal definitions for priapism and prolonged erections, enhances the accuracy and reliability of the results. However, there are some limitations, such as social desirability, confounding factors, and recall bias.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>There is no significant difference in the incidence of priapism in an ICI program in which men combine ICI with tadalafil or sildenafil. However, tadalafil patients had a higher rate of prolonged erections, which was found to occur mostly early during the titration phase.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/jsxmed\/qdad144","type":"journal-article","created":{"date-parts":[[2023,11,17]],"date-time":"2023-11-17T02:41:22Z","timestamp":1700188882000},"page":"29-32","source":"Crossref","is-referenced-by-count":2,"title":["Erectile response profiles of men using PDE5 inhibitors combined with intracavernosal injections as part of a penile rehabilitation program after radical prostatectomy"],"prefix":"10.1093","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7751-0461","authenticated-orcid":false,"given":"Thiago P","family":"Furtado","sequence":"first","affiliation":[{"name":"Sexual and Reproductive Medicine Program, Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center , New York, NY 10022, United States"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3552-5400","authenticated-orcid":false,"given":"Eduardo P","family":"Miranda","sequence":"additional","affiliation":[{"name":"Sexual and Reproductive Medicine Program, Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center , New York, NY 10022, United States"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Serkan","family":"Deveci","sequence":"additional","affiliation":[{"name":"Sexual and Reproductive Medicine Program, Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center , New York, NY 10022, United States"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lawrence","family":"Jenkins","sequence":"additional","affiliation":[{"name":"Sexual and Reproductive Medicine Program, Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center , New York, NY 10022, United States"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph","family":"Narus","sequence":"additional","affiliation":[{"name":"Sexual and Reproductive Medicine Program, Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center , New York, NY 10022, United States"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2141-6489","authenticated-orcid":false,"given":"Christian","family":"Nelson","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Behavioral Sciences, Memorial Sloan Kettering Cancer Center , New York, NY 10017, United States"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John P","family":"Mulhall","sequence":"additional","affiliation":[{"name":"Sexual and Reproductive Medicine Program, Urology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center , New York, NY 10022, United States"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2023,11,16]]},"reference":[{"issue":"20","key":"2024010414220511300_ref1","doi-asserted-by":"crossref","first-page":"2203","DOI":"10.2165\/00003495-200363200-00004","article-title":"Tadalafil","volume":"63","author":"Curran","year":"2003","journal-title":"Drugs"},{"issue":"3","key":"2024010414220511300_ref2","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.eururo.2004.04.025","article-title":"Efficacy of sildenafil citrate at 12 hours after dosing: re-exploring the therapeutic window","volume":"46","author":"Moncada","year":"2004","journal-title":"Eur Urol"},{"issue":"1","key":"2024010414220511300_ref3","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0090-4295(03)00359-5","article-title":"Efficacy of tadalafil for the treatment of erectile dysfunction at 24 and 36 hours after dosing: a randomized controlled trial","volume":"62","author":"Porst","year":"2003","journal-title":"Urology"},{"issue":"9","key":"2024010414220511300_ref4","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1111\/j.1464-410X.2004.04819.x","article-title":"The efficacy and safety of tadalafil: an update","volume":"93","author":"Carson","year":"2004","journal-title":"BJU Int"},{"issue":"2","key":"2024010414220511300_ref5","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1016\/j.urology.2005.02.019","article-title":"Tadalafil-associated priapism","volume":"66","author":"King","year":"2005","journal-title":"Urology"},{"issue":"4","key":"2024010414220511300_ref6","doi-asserted-by":"crossref","first-page":"215","DOI":"10.2209\/tdcpublication.40.215","article-title":"Sildenafil induced priapism","volume":"40","author":"Aoyogi","year":"1999","journal-title":"Bull Tokyo Dent Coll"},{"issue":"6","key":"2024010414220511300_ref7","doi-asserted-by":"crossref","first-page":"950","DOI":"10.1016\/S0090-4295(99)00610-X","article-title":"Sildenafil citrate-associated priapism","volume":"55","author":"Sur","year":"2000","journal-title":"Urology"},{"issue":"4","key":"2024010414220511300_ref8","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1038\/sj.ijir.3901313","article-title":"A prospective randomized study to optimize the dosage of trimix ingredients and compare its efficacy and safety with prostaglandin E1","volume":"17","author":"Seyam","year":"2005","journal-title":"Int J Impot Res"},{"issue":"11","key":"2024010414220511300_ref9","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1111\/j.1464-410X.2012.11080.x","article-title":"A review of outcomes of an intracavernosal injection therapy programme","volume":"110","author":"Coombs","year":"2012","journal-title":"BJU Int"},{"issue":"4","key":"2024010414220511300_ref10","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1016\/S0090-4295(00)00749-4","article-title":"Three-year outcome of a progressive treatment program for erectile dysfunction with intracavernous injections of vasoactive drugs","volume":"56","author":"Baniel","year":"2000","journal-title":"Urology"},{"issue":"1","key":"2024010414220511300_ref11","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/S0022-5347(17)45549-2","article-title":"The ultrastructure of the erectile tissue in priapism","volume":"135","author":"Spycher","year":"1986","journal-title":"J Urol"},{"issue":"4 Pt 2","key":"2024010414220511300_ref12","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1111\/j.1743-6109.2010.01804.x","article-title":"Erectile function rehabilitation in the radical prostatectomy patient","volume":"7","author":"Mulhall","year":"2010","journal-title":"J Sex Med"},{"issue":"4","key":"2024010414220511300_ref13","first-page":"e38186","article-title":"Restoring quality of life: a comprehensive review of penile rehabilitation techniques following prostate surgery","volume":"15","author":"Thakur","year":"2023","journal-title":"Cureus"},{"issue":"Suppl 1","key":"2024010414220511300_ref14","doi-asserted-by":"crossref","first-page":"S38","DOI":"10.1038\/sj.ijir.3900795","article-title":"Rationale for combination therapy of intraurethral prostaglandin E(1) and sildenafil in the salvage of erectile dysfunction patients desiring noninvasive therapy","volume":"14","author":"Nehra","year":"2002","journal-title":"Int J Impot Res"},{"issue":"4","key":"2024010414220511300_ref15","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1046\/j.1464-410X.2000.00790.x","article-title":"Results from different patient populations using combined therapy with alprostadil and sildenafil: predictors of satisfaction","volume":"86","author":"Mydlo","year":"2000","journal-title":"BJU Int"},{"issue":"6","key":"2024010414220511300_ref16","doi-asserted-by":"crossref","first-page":"757","DOI":"10.2164\/jandrol.05035","article-title":"Combination therapy: medicated urethral system for erection enhances sexual satisfaction in sildenafil citrate failure following nerve-sparing radical prostatectomy","volume":"26","author":"Raina","year":"2005","journal-title":"J Androl"},{"issue":"3","key":"2024010414220511300_ref17","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1038\/aja.2011.2","article-title":"Combination therapy for erectile dysfunction: an update review","volume":"13","author":"Dhir","year":"2011","journal-title":"Asian J Androl"},{"issue":"4","key":"2024010414220511300_ref18","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1038\/sj.ijir.3901290","article-title":"Combining programmed intracavernous PGE1 injections and sildenafil on demand to salvage sildenafil nonresponders","volume":"17","author":"Gutierrez","year":"2005","journal-title":"Int J Impot Res"}],"container-title":["The Journal of Sexual Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jsm\/article-pdf\/21\/1\/29\/55013226\/qdad144.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jsm\/article-pdf\/21\/1\/29\/55013226\/qdad144.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,4]],"date-time":"2024-01-04T14:22:29Z","timestamp":1704378149000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jsm\/article\/21\/1\/29\/7424468"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,16]]},"references-count":18,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,11,16]]},"published-print":{"date-parts":[[2023,12,22]]}},"URL":"https:\/\/doi.org\/10.1093\/jsxmed\/qdad144","relation":{},"ISSN":["1743-6095","1743-6109"],"issn-type":[{"value":"1743-6095","type":"print"},{"value":"1743-6109","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,1]]},"published":{"date-parts":[[2023,11,16]]}}}